Purchase this article with an account.
Kazuyuki Hirooka, Tetsuya Baba, Eri Nitta, Kaori Tenkumo, Shino Sato; Preoperative intravitreal bevacizumab on trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factor for surgical failure. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3155.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the prognostic factors for surgical outcomes of intravitreal bavacizumab (IVB) before mitomycin C trabeculectomy for neovascular glaucoma (NVG).
This study is a retrospective, consecutive case series. We reviewed the medical records of 80 patients (80 eyes) with NVG treated at Kagawa University Hospital. The primary endpoint was persistent intraocular pressure (IOP) > 21 mmHg, deterioration of visual acuity to no light perception, and additional glaucoma surgeries. The following variables were assessed as potential prognostic factors for surgical failure: age, etiology of NVG, preoperative IOP, peripheral anterior synechiae (PAS), previous vitrectomy, and previous cataract surgery. Multivariate analysis was performed using the Cox proportional hazard model.
The mean follow-up period was 27.0 months (range, 2 to 77 months). The probability of success 1 and 2 years after trabeculectomy was 87.5% and 81.1%, respectively. In total, 12 of 80 patients were classified as surgical failure. The multivariate model showed that there was no prognostic factor for surgical failure among all NVG patients.
There was no prognostic factor for surgical failure of IVB before mitomycin C trabeculectomy for NVG in all NVG patients.
This PDF is available to Subscribers Only